Ketamine Remission Criteria for Depression Explained

Depression remission after ketamine treatment usually means a patient's score on a standardized rating scale drops below a fixed cutoff, most commonly a score of 10 or lower on the Montgomery-Asberg Depression Rating Scale (MADRS) or 7 or lower on the Hamilton Depression Rating Scale (HAM-D). That is a stricter bar than "response," which only requires at least a 50% reduction in symptom severity from baseline. Because low-dose ketamine is prescribed off-label for depression rather than under a single approved label, there is no ketamine-specific remission standard. Researchers and prescribers generally borrow the same scales and thresholds used across depression trials, then apply them to ketamine's shorter, often session-by-session response pattern.

Remission, Response, and Relapse Are Not the Same

Clinical trials distinguish three outcomes, and mixing them up leads to unrealistic expectations. Response means symptom severity dropped by at least 50% from baseline on a given scale. Remission means the score fell below a set threshold, close to symptom-free, regardless of how large the percentage improvement was. Relapse means symptoms return to a clinically significant level after remission or response was achieved. A patient can respond without reaching remission, and someone who reaches remission after one infusion or dosing session can relapse within weeks if no maintenance plan is in place. If you're evaluating whether ketamine is a fit for your situation, understanding this distinction matters as much as reviewing low-dose ketamine clinical eligibility criteria before starting.

What the Ketamine Evidence Actually Shows

A 2013 two-site randomized trial published in The American Journal of Psychiatry found that a single intravenous ketamine infusion produced a treatment response, at least a 50% reduction in MADRS score, in roughly two-thirds of participants with treatment-resistant depression (TRD) at 24 hours, compared with about one-quarter given an active placebo (Murrough et al., PubMed). Remission, the stricter outcome, was reported at meaningfully lower rates than response in that trial and in most that followed it, and both response and remission commonly faded within one to two weeks without repeat dosing.

That pattern, strong short-term response but inconsistent and often brief remission, is why single-dose or short-course ketamine research doesn't map cleanly onto remission statistics from longer-acting antidepressants. The NIH-funded STAR*D trial, which followed patients through sequential standard antidepressant trials, found only about one in three reached remission on QIDS-SR16 criteria after the first treatment step (NIMH, STAR*D). Ketamine studies are not directly comparable to that benchmark because dosing schedules, follow-up windows, and patient populations differ, but the comparison illustrates why researchers grade ketamine's remission evidence as promising and short-term positive rather than settled.

How Remission Gets Tracked in Practice

Most clinics track progress with repeated scale scores rather than a single end-of-treatment snapshot. A prescriber-administered scale like MADRS or HAM-D is more resistant to day-to-day mood variation than a one-time self-report, but many practices also use the self-rated PHQ-9 between visits because it's fast and doesn't require a clinician to administer. Consistency matters more than which scale is chosen: the same instrument, given at the same intervals against the same documented baseline, is what makes a remission claim meaningful. Patients tracking their own response between sessions can use structured tools, such as those covered in how to track symptoms between ketamine treatments, to give their prescriber usable data rather than a general impression of feeling better or worse.

Age and comorbidity also shape how remission is interpreted. Older adults may show slower or more variable symptom-scale changes, which is one reason protocols for this group get extra scrutiny; see ketamine therapy for older adults safety for what that monitoring typically involves. Patients on multiple medications, a common scenario in low-dose ketamine for late-life depression with multiple medications, may need adjusted follow-up intervals since interacting drugs can mask or exaggerate scale changes. Reviewing common side effects alongside symptom tracking helps separate a true remission trend from a temporary dosing-day effect.